Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation
Master Docket Number: | 1:24-md-3092 |
Presiding Judge: | J. Philip Calabrese |
MDL Clerk: |
Corey McCardle |
Chambers Contact: | Angela Yesiolowski 216-357-7265 |
Description: | These actions share complex factual questions arising from the alleged propensity of Suboxone film, which is used for the treatment of opiate addiction, to cause dental erosion and decay. Plaintiffs in all actions allege that defendants designed Suboxone film to be acidic, which they claim leads to dental erosion and decay when the film is dissolved in the mouth (Suboxone previously was available only as an ingestible tablet). Plaintiffs allege that defendants knew, but failed to warn, that Suboxone film causes damage to teeth. The same factual questions regarding general causation, including the mechanism of the alleged injury, are present in all cases. Similarly common are questions surrounding the adequacy of the testing defendants conducted regarding Suboxone film and the sufficiency of warnings regarding dental problems. |
Plaintiffs' Co-Lead Counsel: |
Ashlie Case Sletvold Erin K. Copeland Timothy J. Becker Trent B. Miracle |
Plaintiffs' Executive Committee: |
Alyson Steele Beridon C. Andrew Childers Lee Floyd Layne Hilton Russ Abney |
Plaintiffs' Liaison Counsel: |
Alyson Steele Beridon HERZFELD, SUETHOLZ, GASTEL, LENISKI, AND WALL, PLLC 600 Vine Street, Suite 2720 Cincinnati, Ohio 45202 (513) 381-2224 alyson@hsglawgroup.com |
Counsel for Defendants: |
Denise A. Dickerson Mary Renee Pawelek Matthew L. Streety Randall L. Christian |
Orders Pertaining to MDL 3092
Doc #1 | 02/05/2024 | Initial Transfer Order from Judicial Panel on Multidistrict Litigation |
Doc #7 | 02/07/2024 | Case Management Order No. 1 (Initial Status Conference) |
Doc #35 | 03/08/2024 | Case Management Order No. 2 (Plaintiff's Leadership) |
Doc #52 | 03/27/2024 | Amended Case Management Order No. 3 (Direct Filing) |
Doc #81 | 05/16/2024 | Case Management Order No. 4 ("Schedule A" Complaint) |
Doc #84 | 05/21/2024 | Case Management Order No. 5 (Designation and Handling of Protected Information) |
Doc #85 | 05/21/2024 | Case Management Order No. 6 (Evidence Rule 502(d) and Privileged Materials) |
Doc #93 | 06/06/2024 | Case Management Order No. 7 (Plaintiffs' Leadership Development Committee) |
Doc #98 | 06/11/2024 | Case Management Order No. 8 (Protocol for Common-Benefit Fees and Expenses) |
Doc #103 | 06/24/2024 | Opinion and Order denying Defendants' motion for phased discovery on general causation |
Doc# 132 | 08/08/2024 | Case Management Order No. 9 (Appointing Plaintiffs' Leadership Development Committee) |
Doc #133 | 08/08/2024 | Case Management Order No. 10 (Additional Appointment to Plaintiffs' Steering Committee) |
Doc #136 | 08/28/2024 | Case Management Order No. 11 (ESI Protocol) |
Doc # 146 | 09/10/2024 | Opinion and Order dismissing without prejudice Defendants Indivior PLC, Reckitt Benckiser LLC, and Reckitt Benckiser Healthcare (UK) Ltd. |